# Study to Assess the Safety of a New GSK Biologicals' GSK2231395A Candidate Vaccine

> **NCT00849069** · PHASE1 · TERMINATED · sponsor: **GlaxoSmithKline** · enrollment: 30 (estimated)

## Conditions studied

- Haemophilus Influenzae
- Streptococcus Pneumoniae

## Interventions

- **BIOLOGICAL:** GSK2231395A
- **BIOLOGICAL:** TwinrixTM

## Key facts

- **NCT ID:** NCT00849069
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-03-12
- **Primary completion:** 2009-04-07
- **Final completion:** 2009-04-07
- **Target enrollment:** 30 (ESTIMATED)
- **Why stopped:** The study has been stopped for logistic reasons not related to the safety or efficacy of the vaccine.
- **Last updated:** 2017-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00849069

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00849069, "Study to Assess the Safety of a New GSK Biologicals' GSK2231395A Candidate Vaccine". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00849069. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*